The goal of this clinical trial is to determine whether the LNG-IUS is more effective to that of expectant in preventing endometrial polyp recurrence after hysteroscopic polypectomy. Researchers will compare LNG-IUS to expectant management to see if LNG-IUS works to reduce the recurrence rate of endometrial polyps. Participants will: Receive Mirena placement or not after hysteroscopic polypectomy; Be scheduled for a follow-up with TVCD to screen for endometrial polyps recurrence every 6 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
558
Participants in the intervention group will receive Mirena placement after hysteroscopic polypectomy
Endometrial polyps recurrence rate
Time frame: 2 years
Side effects and complications
Time frame: 2 years
Visual Analogue Scale (VAS) score for chronic pelvic pain
The minimum value of this scoring table is 0, and the maximum value is 10. The higher the score, the higher the degree of pain.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.